{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:01:57Z","timestamp":1785164517044,"version":"3.55.0"},"reference-count":57,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Coronary stenting remains the cornerstone of interventional cardiology. Drug-eluting stents (DES) have reduced restenosis compared to bare-metal stents (BMS), but their high cost and need for prolonged dual antiplatelet therapy (DAPT) limit accessibility in many regions. Recent evidence has revisited the potential role of systemic pharmacologic adjuncts\u2014oral sirolimus (rapamycin), prednisone and colchicine\u2014as cost-effective therapies to mitigate restenosis and adverse events following BMS implantation. Objective: This review critically evaluates the clinical and mechanistic evidence supporting the use of oral immunosuppressive or anti-inflammatory drugs following BMS implantation, with emphasis on their applicability in both resource-limited and general cardiology settings. Three randomized clinical trials comparing this strategy against DES are analyzed and discussed in this review. Conclusions: Oral sirolimus, prednisone, and colchicine demonstrate promising anti-inflammatory and antiproliferative effects that translate into clinical outcomes comparable to DES in a highly select population. Their systemic administration following BMS implantation may provide a feasible, cost-effective alternative where DES use is restricted by cost or clinical contraindications. Larger-scale, long-term trials are warranted to confirm safety, optimize dosing, and identify ideal patient populations for this \u201cpharmacologic stent hybrid\u201d strategy.<\/jats:p>","DOI":"10.3390\/biomedicines14081685","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:08:14Z","timestamp":1785161294000},"page":"1685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Use of Oral Rapamycin, Prednisone and Colchicine After Coronary Bare-Metal Stent Implantation: Narrative Review of Randomized Clinical Trials"],"prefix":"10.3390","volume":"14","author":[{"given":"Carlos","family":"Fernandez-Pereira","sequence":"first","affiliation":[{"name":"Cardiac Unit, Cardiovascular Research Center (CECI), Otamendi Hospital, Buenos Aires 1001, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-0335","authenticated-orcid":false,"given":"Alfredo E.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Cardiac Unit, Cardiovascular Research Center (CECI), Otamendi Hospital, Buenos Aires 1001, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.CIR.91.5.1397","article-title":"Coronary Stenting Decreases Restenosis in Lesions with Early Loss in Luminal Diameter 24 Hours After Successful PTCA","volume":"91","author":"Rodriguez","year":"1995","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease","volume":"331","author":"Serruys","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.294.10.1215","article-title":"Comparison of a polymer based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial","volume":"294","author":"Stone","year":"2005","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jacc.2005.10.016","article-title":"Coronary stent thrombosis in the current drug eluting stent era: Insights from the ERACI III trial","volume":"47","author":"Rodriguez","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","first-page":"C39","article-title":"Identifying stent thrombosis, a critical appraisal of the Academic Research Consortium (ARC) consensus definitions: A lighthouse and as a toe in the water","volume":"4","author":"Vranckx","year":"2008","journal-title":"EuroIntervention"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.111.046599","article-title":"Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: Five-year outcome of the j-Cypher Registry","volume":"125","author":"Kimura","year":"2012","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4244\/EIJ-D-22-00526","article-title":"Sirolimus-eluting or everolimus-eluting stents for coronary artery disease: 5-year outcomes of the randomised BIOFLOW-IV trial","volume":"18","author":"Slagboom","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","article-title":"The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.amjcard.2021.12.037","article-title":"Long-Term Intracoronary Structural and Vasomotor Assessment of the ABSORB Bioresorbable Vascular Scaffold","volume":"168","author":"Altisent","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.122.062714","article-title":"ISCHEMIA-EXTEND Research Group. Survival After Invasive or Conservative Management of Stable Coronary Disease","volume":"147","author":"Hochman","year":"2023","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rodriguez, A.E., Fernandez-Pereira, C., Mieres, J.R., and Rodriguez-Granillo, A.M. (2023). High Non-Cardiac Death Incidence Should Be a Limitation of Drug-Eluting Stents Implantation? Insights from Recent Randomized Data. Diagnostics, 13.","DOI":"10.3390\/diagnostics13071321"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1001\/jamainternmed.2020.4748","article-title":"Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions with Coronary Bypass Surgery: A Meta-analysis","volume":"180","author":"Gaudino","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1056\/NEJMoa1909406","article-title":"EXCEL Trial Investigators. Five-year outcomes after PCI or CABG for left main coronary disease","volume":"381","author":"Stone","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rodriguez-Granillo, A.M., Sol\u00f3rzano, L., Vladimir P\u00e9rez-Oma\u00f1a, G., Ascarrunz, D., Pavlovsky, H., Gomez-Valerio, R., Bertr\u00e1n, I., Flores, F., Parra, J., and Guiroy, J. (2024). Trends in primary percutaneous coronary intervention for the treatment of acute coronary ST-elevation myocardial infarction in Latin American countries: Insights from the CECI consortium. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1275907"},{"key":"ref_17","unstructured":"(2026, April 21). Bare Metal Coronary Artery Stent Market Size, Share, Growth, and Industry Analysis, By Type (Co-Cr Stent, Pt-Cr Stent, Others), By Application (For Large Vessel (Above 3mm), For Small Vessel (Below 3mm)), Regional Insights and Forecast to 2035. Available online: https:\/\/www.industryresearch.biz\/market-reports\/bare-metal-coronary-artery-stent-market-116356."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.RES.76.3.412","article-title":"Rapamycin inhibits cell cycle regulators of proliferation in vascular smooth muscle cells","volume":"76","author":"Marx","year":"1995","journal-title":"Circ. Res."},{"key":"ref_20","first-page":"1323","article-title":"Vascular inflammation and repair: Implications for re-endothelialization, restenosis, and stent thrombosis","volume":"57","author":"Inoue","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1026188200939","article-title":"Increase in interleukin-6 in the first hour after coronary stenting: An early marker of the inflammatory response","volume":"15","author":"Aggarwal","year":"2003","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1161\/01.CIR.99.16.2164","article-title":"Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle","volume":"99","author":"Gallo","year":"1999","journal-title":"Circulation"},{"key":"ref_23","first-page":"581","article-title":"Pilot study of oral rapamycin to prevent restenosis in patients undergoing Coronary stent therapy: Argentina Single-Center Study (ORAR Trial)","volume":"15","author":"Rodriguez","year":"2003","journal-title":"J. Invasive Cardiol."},{"key":"ref_24","first-page":"1386","article-title":"Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study","volume":"44","author":"Waksman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/hrt.2004.050617","article-title":"Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: Results of the Argentina single centre study (ORAR trial)","volume":"91","author":"Rodriguez","year":"2005","journal-title":"Heart"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000253854","article-title":"Preventing restenosis after implantation of bare stents with oral rapamycin: A randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up","volume":"115","author":"Cernigliaro","year":"2010","journal-title":"Cardiology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.0000138935.17503.35","article-title":"Randomized, double-blind, placebo controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial","volume":"110","author":"Hausleiter","year":"2004","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.jacc.2005.12.052","article-title":"Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study","volume":"47","author":"Rodriguez","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","first-page":"317","article-title":"Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation","volume":"75","author":"Stojkovic","year":"2010","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4244\/EIJV5I2A40","article-title":"Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: Long-term follow-up results from the randomized, controlled ORAR III (Oral Rapamycin in ARgentina) study","volume":"5","author":"Maree","year":"2009","journal-title":"EuroIntervention"},{"key":"ref_31","first-page":"385","article-title":"Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug eluting stents: Three-year outcome from the randomized oral rapamycinin Argentina (ORAR) III trial","volume":"80","author":"Rodriguez","year":"2012","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.amjcard.2013.11.033","article-title":"Comparison of cost-effectiveness of oral rapamycin plus bare-metal stents versus first generation of drug-eluting stents (from the Randomized Oral Rapamycin in Argentina [ORAR] 3 trial)","volume":"113","author":"Rodriguez","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in Acute Myocardial Infarction","volume":"392","author":"Jolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacc.2009.04.077","article-title":"5-Year clinical outcomes after sirolimus eluting stent implantation: Insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents","volume":"54","author":"Caixeta","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.amjcard.2013.05.074","article-title":"Systematic review of effectiveness of oral sirolimus after bare-metal stenting of coronary arteries for prevention of in-stent restenosis","volume":"112","author":"Dasari","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0002-8703(99)70247-4","article-title":"Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation","volume":"138","author":"Lee","year":"1999","journal-title":"Am. Heart J."},{"key":"ref_37","first-page":"227","article-title":"A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty","volume":"18","author":"Stone","year":"1989","journal-title":"Catheter. Cardiovasc. Diagn."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4244\/EIJV5I2A39","article-title":"Long term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C- reactive protein levels","volume":"5","author":"Ferrero","year":"2009","journal-title":"EuroIntervention"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0735-1097(02)02562-7","article-title":"Immunosuppressive therapy for the prevention of restenosis after coronarya rtery stent implantation (IMPRESS Study)","volume":"40","author":"Versaci","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/eurheartj\/eht079","article-title":"Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES)","volume":"34","author":"Ribichini","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.atherosclerosis.2014.09.021","article-title":"ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: A patient-level meta-analysis of randomized trials","volume":"237","author":"Cassese","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11926-002-0073-2","article-title":"Update on colchicine and its mechanism of action","volume":"4","author":"Molad","year":"2002","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1074248413499972","article-title":"Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease","volume":"19","author":"Nidorf","year":"2014","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/0735-1097(92)90624-V","article-title":"Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty","volume":"19","author":"McCallister","year":"1992","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients","volume":"61","author":"Deftereos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1093\/eurheartj\/ehaf210","article-title":"Colchicine for secondary prevention of vascular events: A meta-analysis of trials","volume":"46","author":"Poorthuis","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e009992","DOI":"10.1161\/CIRCINTERVENTIONS.120.009992","article-title":"Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention: The COPE-PCI Pilot Trial","volume":"14","author":"Cole","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e008717","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","article-title":"Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial","volume":"13","author":"Shah","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/fca-2020-0161","article-title":"Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention","volume":"17","author":"Gallardo","year":"2021","journal-title":"Future Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rodriguez-Granillo, A.M., Mieres, J., Fernandez-Pereira, C., Sadouet, C.C., Milei, J., Swieszkowski, S.P., Stutzbach, P., Santaera, O., Wainer, P., and Rokos, J. (2025). Randomized Clinical Trial Comparing Bare-Metal Stents Plus Colchicine Versus Drug-Eluting Stents for Preventing Adverse Cardiac Outcomes: Three-Year Follow-Up Results of the ORal Colchicine in Argentina (ORCA) Trial. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092871"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s10554-017-1146-7","article-title":"Comparison of in-stent neoatherosclerosis and tissue characteristics between early and late in-stent restenosis in second-generation drug-eluting stents: An optical coherence tomography study","volume":"33","author":"Sabbah","year":"2017","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"NORSTENT Investigators. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease","volume":"375","author":"Mannsverk","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(19)30474-X","article-title":"Coronary Stent Trialists\u2019 Collaboration. Drug-eluting or bare-metal stents for percutaneous coronary intervention: A systematic review and individual patient data meta-analysis of randomised clinical trials","volume":"393","author":"Piccolo","year":"2019","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e018828","DOI":"10.1161\/JAHA.120.018828","article-title":"Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization","volume":"10","author":"Piccolo","year":"2021","journal-title":"J. Am. Heart Assoc."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/8\/1685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:33:08Z","timestamp":1785162788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/8\/1685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biomedicines14081685"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines14081685","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}